OncoSil Medical Limited (ASX:OSL) Expands German Hospital Network by 43%
Operational Achievements
OncoSil Medical Limited (ASX:OSL) has announced that 120 German hospitals are now authorized to negotiate funding for the OncoSil™ device under the NUB program with statutory health insurance companies. This marks a 43% increase from 84 hospitals in 2024, highlighting growing demand and recognition of the device within Germany’s healthcare system.
Regulatory Approvals
The Company received a “Positive Status 1” classification for the OncoSil™ device in 2021. In October 2024, the German Federal Joint Committee approved the directive for testing the new treatment method involving endoscopic injection-implantation of Phosphorous-32 labeled microparticles. In January 2025, the Ministry of Health granted approval, and the Coverage with Evidence Development Study Directive was published in the National German Gazette.
Executive Comments
Nigel Lange, CEO & Managing Director of OncoSil Medical, stated, “We are delighted by the continued progress in Germany with the expanded authorisation for hospitals to negotiate funding for the OncoSil™ device under the NUB innovation program. This important milestone reflects growing acceptance of the OncoSil device by the German healthcare professionals on the clinical potential of our treatment and reinforces our commitment to delivering life-changing solutions for patients with locally advanced pancreatic cancer. The approval from the German Ministry of Health and the publication of the Coverage with Evidence Development Study Directive further solidifies our position in this important market. We remain dedicated to advancing innovative treatments that improve patient outcomes worldwide.”
Motley Fool contributor Abbie Stokes has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.